Mark Purcell
Stock Analyst at Morgan Stanley
(1.08)
# 3,585
Out of 4,761 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $109.35 | +4.25% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $54.46 | +0.99% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $36.64 | +20.09% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $74.22 | +14.52% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $88.08 | +36.24% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $109.35
Upside: +4.25%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $54.46
Upside: +0.99%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $36.64
Upside: +20.09%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $74.22
Upside: +14.52%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $88.08
Upside: +36.24%